Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Gastric Cancer Management and Outcomes, and Lung Cancer Research Studies.
Macrophage membrane-coated NIR light-photodegradable carbon nitride-based gene vectors for gas-gene therapy of liver fibrosis
Tumor Cell Membrane‐Coated Oxygen‐Evolving Carbon Nitride Nanozymes Combined with Curcumenol Delivery for Lung Cancer Therapy via ‘Open‐Source Throttling’ Strategy
Dux activates metabolism-lactylation-MET network during early iPSC reprogramming with Brg1 as the histone lactylation reader
Out-of-Africa migration and clonal expansion of a recombinant Epstein-Barr virus drives frequent nasopharyngeal carcinoma in southern China
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment
A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].